HC Wainwright restated their buy rating on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a report published ...

Syndax Pharmaceuticals Inc (SNDX) reports promising revenue from Revv Forge launch and outlines strategic growth plans, ...

Highlights,Target price adjustments for Syndax Pharmaceuticals reflect varied market sentiment.,Executive decisions on stock ...

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) had its price target lifted by analysts at JPMorgan Chase & Co. from ...

Q4 2024 Earnings Call Transcript March 3, 2025 Operator: Good day, everyone, and welcome to the Syndax Fourth Quarter and Full Year 2024 Earnings Conference Call. Today’s call is being recorded.

Syndax Pharmaceuticals, Inc. NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of ...

Reports Q4 revenue $7.68M vs $0 last year. “We are off to a strong start with the U.S. launch of Revuforj and are very encouraged by the early ...

Syndax Pharmaceuticals Inc. ( ($SNDX) ) has released its Q4 earnings. Here is a breakdown of the information Syndax Pharmaceuticals Inc. presented ...

Syndax Pharmaceuticals reported strong early results for its newly launched products, achieving $7.7 million in net revenue from Revuforj® (revumenib) in just five weeks following its U.S. launch.

WALTHAM, Mass. — WALTHAM, Mass. — Syndax Pharmaceuticals Inc. (SNDX) on Monday reported a loss of $94.2 million in its fourth quarter. On a per-share basis, the Waltham, Massachusetts-based company ...

About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj ® ...